Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BMY

Bristol-Myers Squibb Co.

Jul 26 • 04:00PM ET

50.45

Dollar change +5.18
Percentage change 11.44	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO SCHD SPY IVV VTV XLV COWZ DGRO MOAT

Scroll to Statements

Index	S&P 500	P/E	-	EPS (ttm)	-3.10	Insider Own	0.07%	Shs Outstand	2.03B	Perf Week	18.32%
Market Cap	102.27B	Forward P/E	7.36	EPS next Y	6.85	Insider Trans	0.00%	Shs Float	2.03B	Perf Month	18.71%
Income	-6148.00M	PEG	-	EPS next Q	1.62	Inst Own	82.41%	Short Float	1.58%	Perf Quarter	12.86%
Sales	45.53B	P/S	2.25	EPS this Y	-92.58%	Inst Trans	-0.74%	Short Ratio	2.05	Perf Half Y	1.69%
Book/sh	8.14	P/B	6.20	EPS next Y	1128.60%	ROA	-6.36%	Short Interest	32.06M	Perf Year	-20.44%
Cash/sh	4.77	P/C	10.57	EPS next 5Y	-4.63%	ROE	-25.45%	52W Range	39.35 - 63.89	Perf YTD	-1.68%
Dividend Est.	2.41 (4.78%)	P/FCF	8.18	EPS past 5Y	5.14%	ROI	-9.10%	52W High	-21.04%	Beta	0.43
Dividend TTM	2.37 (4.70%)	Quick Ratio	0.99	Sales past 5Y	16.92%	Gross Margin	55.85%	52W Low	28.21%	ATR (14)	1.45
Dividend Ex-Date	Jul 05, 2024	Current Ratio	1.11	EPS Y/Y TTM	-189.43%	Oper. Margin	16.55%	RSI (14)	81.86	Volatility	3.43% 2.77%
Employees	34100	Debt/Eq	3.48	Sales Y/Y TTM	-0.68%	Profit Margin	-13.50%	Recom	2.72	Target Price	49.82
Option/Short	Yes / Yes	LT Debt/Eq	3.10	EPS Q/Q	-650.00%	Payout	59.82%	Rel Volume	2.30	Prev Close	45.27
Sales Surprise	5.73%	EPS Surprise	27.81%	Sales Q/Q	4.66%	Earnings	Jul 26 BMO	Avg Volume	15.61M	Price	50.45
SMA20	21.16%	SMA50	20.55%	SMA200	4.04%	Trades		Volume	35,856,963	Change	11.44%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-11-24	Downgrade	Societe Generale	Buy → Hold
Feb-06-24	Downgrade	Redburn Atlantic	Buy → Neutral	$77 → $54
Jan-03-24	Downgrade	BofA Securities	Buy → Neutral	$68 → $60
Nov-15-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$68 → $55
Nov-09-23	Initiated	Deutsche Bank	Hold	$55
Nov-02-23	Downgrade	Daiwa Securities	Outperform → Neutral	$68 → $54
Oct-27-23	Upgrade	HSBC Securities	Reduce → Hold	$55 → $53
Oct-27-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-27-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$60
Oct-20-23	Resumed	UBS	Neutral	$70 → $60
Jul-14-23	Initiated	HSBC Securities	Reduce	$56
Jul-10-23	Initiated	SVB Securities	Market Perform	$66
Jun-28-23	Initiated	Daiwa Securities	Outperform	$70
Mar-06-23	Initiated	Jefferies	Hold	$62
Jan-17-23	Initiated	Cantor Fitzgerald	Overweight	$95
Nov-18-22	Initiated	Credit Suisse	Neutral	$78
Oct-10-22	Downgrade	Guggenheim	Buy → Neutral
Sep-14-22	Downgrade	Berenberg	Buy → Hold	$82 → $76
Jun-03-22	Downgrade	Raymond James	Outperform → Mkt Perform
Apr-06-22	Resumed	Morgan Stanley	Underweight	$64

Show Previous Ratings

Today 01:26PM	Stocks jump on cool inflation data, 3M pops on earnings: Yahoo Finance (Yahoo Finance Video) +11.44%
11:33AM	Stocks to Watch Friday: DexCom, 3M, Coinbase, Charter (The Wall Street Journal)
10:36AM	Bristol-Myers Squibb Beats Q2 Expectations, Boosts Guidance on Rising Drug Sales (Investopedia)
10:30AM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
08:55AM	Stock Futures Rise as Chip Shares Rally (The Wall Street Journal)
06:59AM	Loading…
06:59AM	Bristol Myers Squibb Reports Second Quarter Financial Results for 2024 (Business Wire)
04:57AM	Pressure on Stocks Eases at End of Turbulent Week (The Wall Street Journal)
Jul-25-24 06:03PM	June PCE, Bristol Myers Squibb earnings: What to watch Friday (Yahoo Finance Video)
Jul-19-24 06:59AM	Bristol Myers Squibb Receives European Medicines Agency Validation of Application for Opdivo (nivolumab) plus Yervoy (ipilimumab) for First-Line Treatment of Unresectable or Advanced Hepatocellular Carcinoma (Business Wire)
Jul-11-24 02:23PM	3 Under-$10 Biotech Stocks That Could Make You Rich (InvestorPlace)
Jul-10-24 12:00PM	3 Undervalued Stocks Ready for a Breakout This Summer (InvestorPlace)
Jul-09-24 07:40AM	The 7 Best Warren Buffett Stocks to Buy in July 2024 (InvestorPlace)
Jul-08-24 06:59AM	Bristol Myers Squibb to Participate in UBS Virtual Targeted Protein Degradation Day (Business Wire)
06:43AM	3 Defensive Stocks to Buy During the Market Dip (InvestorPlace)
Jul-05-24 06:45AM	3 Hidden Stock Gems That Wall Street Is Overlooking (InvestorPlace)
10:13AM	Loading…
Jun-30-24 10:13AM	Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn't Discovered Yet (InvestorPlace)
Jun-27-24 01:14PM	You've Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever. (InvestorPlace)
Jun-23-24 01:38PM	7 Dividend Stocks to Buy Now: June 2024 (InvestorPlace)
Jun-21-24 07:30PM	Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) (Business Wire)
06:59AM	European Medicines Agency Validates Bristol Myers Squibbs Application for Subcutaneous Nivolumab (Business Wire)
Jun-20-24 06:59AM	Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024 (Business Wire)
Jun-19-24 02:17PM	3 Warren Buffett Stocks to Buy Now: June 2024 (InvestorPlace)
01:09PM	From Comfort to Cure: 2024 ASCO Meeting Reveals Groundbreaking Oncology Data (PR Newswire)
Jun-18-24 04:16PM	Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors (Business Wire)
06:59AM	Bristol Myers Squibb Announces Dividend (Business Wire)
Jun-17-24 03:27PM	7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline (InvestorPlace)
09:45AM	Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase (GlobeNewswire)
Jun-14-24 06:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
Jun-13-24 04:46PM	U.S. Food and Drug Administration Approves Augtyro (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors (Business Wire)
09:00AM	The Lustgarten Foundation Appoints Two New Board Members (PR Newswire)
01:50AM	Loading…
Jun-12-24 01:50AM	Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb (ACCESSWIRE)
Jun-11-24 11:52AM	Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974 ( ERISA ) (Brower Piven Release) (GlobeNewswire)
10:00AM	3 Penny Stocks to Buy if You Want to Spend Less and Earn More (InvestorPlace)
Jun-10-24 12:00PM	7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too) (InvestorPlace)
Jun-08-24 09:00AM	The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024 (InvestorPlace)
Jun-05-24 09:49AM	Here's Why Jim Cramer Says You Should Not Buy Bristol-Myers Squibb Co (NYSE:BMY) (Insider Monkey)
09:42AM	Jim Cramer Says You Should Not Buy These 11 Stocks (Insider Monkey)
09:30AM	Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic Pipeline and Expand Depth and Breadth of Commercial Offerings (PR Newswire)
07:00AM	I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers (PR Newswire)
Jun-04-24 08:00AM	Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial (Business Wire)
06:59AM	Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
Jun-03-24 10:13AM	Bristol Myers Squibbs Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO Annual Meeting (Business Wire)
08:00AM	Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer (Business Wire)
Jun-01-24 08:00AM	KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer (Business Wire)
May-31-24 08:04AM	Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2023 Earnings Call Transcript (Insider Monkey)
May-30-24 11:51AM	U.S. Food and Drug Administration Approves Bristol Myers Squibbs Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma (Business Wire)
11:05AM	Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974 ( ERISA ) (Brower Piven Release) (GlobeNewswire)
06:10AM	7 Underappreciated Stocks With 25% Return Potential in 2024 (InvestorPlace)
May-29-24 06:59AM	Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma (Business Wire)
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
10:15AM	ASPIRE: Our Commitment To Address Health Inequities in Low- and Middle-Income Countries (ACCESSWIRE)
May-27-24 06:13AM	3 Blue-Chip Stocks to Buy at 52-Week Lows in May (InvestorPlace)
May-23-24 07:22PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
05:05PM	Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms (Business Wire)
12:03PM	Corporate Employers Accused of Increasing Risk Of Pension Shortfalls in Violation of Employee Retirement Income Security Act of 1974 ( ERISA ) (Brower Piven Release) (GlobeNewswire)
06:59AM	Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting (Business Wire)
May-22-24 01:44PM	Pfizer to Cut Costs in Multi-Year Effort (The Wall Street Journal)
11:15AM	Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries (ACCESSWIRE)
03:30AM	NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb (PR Newswire)
May-21-24 08:45AM	Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign (Business Wire)
07:45AM	3 Bargain Stocks to Buy Now: May 2024 (InvestorPlace)
06:59AM	Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase) (Business Wire)
May-16-24 10:26AM	New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis (Business Wire)
07:15AM	7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs (InvestorPlace)
May-15-24 08:57PM	Bristol Myers Squibbs CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma (Business Wire)
07:00AM	Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Q1 2024 Results (GlobeNewswire)
May-14-24 06:46AM	Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders (InvestorPlace)
May-13-24 12:41PM	One stock is dragging down the S&P 500's earnings growth (Yahoo Finance)
May-10-24 04:55PM	Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint (The Wall Street Journal)
04:30PM	Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial (Business Wire)
May-09-24 03:38PM	Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 07:00AM	Immunocore reports first quarter financial results and provides a business update (GlobeNewswire)
07:00AM	Editas Medicine Announces First Quarter 2024 Results and Business Updates (GlobeNewswire)
May-07-24 06:59AM	Bristol Myers Squibb to Participate in Upcoming Investor Conferences (Business Wire)
May-06-24 02:22PM	Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields (InvestorPlace)
06:59AM	U.S. Food and Drug Administration Accepts Bristol Myers Squibbs Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase) (Business Wire)
06:59AM	European Medicines Agency Validates Bristol Myers Squibbs Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite... (Business Wire)
06:00AM	Uncover the Potential: 3 Discounted Stocks Ready for a Comeback (InvestorPlace)
May-03-24 10:34AM	Geron Corporation (NASDAQ:GERN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-01-24 08:00AM	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration (GlobeNewswire)
Apr-30-24 01:52PM	Alphabet Inc. (NASDAQ:GOOG) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:37AM	PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Call Transcript (Insider Monkey)
05:00AM	Scenic Biotech Enters into Research Collaboration with Bristol Myers Squibb (Business Wire)
Apr-29-24 06:00AM	Repertoire Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases (PR Newswire)
Apr-26-24 06:59AM	CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibbs Opdivo (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma (Business Wire)
Apr-25-24 04:41PM	Bristol Myers Squibb stock tumbles on cost-cutting initiative (Yahoo Finance Video) -8.51%
03:35PM	Major drugmakers are bracing to lose their most lucrative patents this decade (Quartz)
02:02PM	Analyst Report: Bristol-Myers Squibb Company (Morningstar Research)
01:32PM	Stocks sink on GDP, tech giants Microsoft, Alphabet report results: Yahoo Finance (Yahoo Finance Video)
11:55AM	BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
11:50AM	Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts (InvestorPlace)
11:48AM	Bristol-Myers (BMY) Q1 Loss Narrower Than Expected, Sales Beat (Zacks)
11:42AM	Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma (The Wall Street Journal)
09:49AM	Bristol-Myers Squibb to Cut 2,200 Jobs as Part of $1.5 Billion Cost-Cutting Effort (The Wall Street Journal)
06:59AM	Bristol Myers Squibb Reports First Quarter Financial Results for 2024 (Business Wire)
Apr-22-24 01:56PM	Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know (Zacks)
06:59AM	Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster (Business Wire)
Apr-11-24 09:10AM	Building a Better Future: Bristol Myers Squibb 2023 ESG Report (ACCESSWIRE)
Apr-08-24 11:30AM	KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) (Business Wire)
07:00AM	Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals (ACCESSWIRE)

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shanahan Karin	EVP, Glob. Prod. Dev. & Supply	Apr 01 '24	Option Exercise	0.00	3,306	0	6,532	Apr 02 06:45 PM
Lenkowsky Adam	EVP, Chief Commercial Officer	Mar 10 '24	Option Exercise	0.00	15,016	0	13,859	Mar 12 09:54 PM
LEUNG SANDRA	EVP, General Counsel	Mar 10 '24	Option Exercise	0.00	46,784	0	371,312	Mar 12 09:43 PM
Plenge Robert M	EVP, Chief Research Officer	Mar 10 '24	Option Exercise	0.00	9,143	0	15,182	Mar 12 09:21 PM
Poole Ahn Amanda	EVP, Chief Human Resources	Mar 10 '24	Option Exercise	0.00	5,458	0	4,841	Mar 12 09:11 PM
Hirawat Samit	EVP,Chief Med.Offr.,Drug Dev.	Mar 10 '24	Option Exercise	0.00	38,388	0	80,256	Mar 12 08:40 PM
Holzer Phil M	SVP and Controller	Mar 10 '24	Option Exercise	0.00	5,520	0	14,916	Mar 12 08:31 PM
Hoch Lynelle	President, Cell Therapy Org.	Mar 10 '24	Option Exercise	0.00	4,351	0	3,781	Mar 12 08:01 PM
Gallman Cari	EVP, Corporate Affairs	Mar 10 '24	Option Exercise	0.00	2,761	0	2,655	Mar 12 08:00 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Mar 10 '24	Option Exercise	0.00	54,638	0	129,769	Mar 12 07:58 PM
Elkins David V	EVP, Chief Financial Officer	Mar 10 '24	Option Exercise	0.00	64,326	0	225,111	Mar 12 05:43 PM
Caforio Giovanni	Executive Chair of the Board	Mar 10 '24	Option Exercise	0.00	190,130	0	529,662	Mar 12 05:42 PM
Meyers Gregory Scott	EVP, Chief Digital & Tech Off.	Feb 01 '24	Option Exercise	0.00	2,543	0	6,040	Feb 05 07:10 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Dec 05 '23	Buy	49.78	2,000	99,560	82,672	Dec 07 06:06 PM
Plenge Robert M	EVP, Chief Research Officer	Dec 02 '23	Option Exercise	0.00	616	0	7,200	Dec 05 06:23 PM
Elkins David V	EVP, Chief Financial Officer	Dec 02 '23	Option Exercise	0.00	8,792	0	172,342	Dec 05 06:22 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Dec 02 '23	Option Exercise	0.00	2,638	0	82,022	Dec 05 06:21 PM
BOERNER CHRISTOPHER S.	Chief Executive Officer	Nov 28 '23	Buy	48.86	3,071	150,049	79,384	Nov 30 06:32 PM
Samuels Theodore R. II	Director	Nov 20 '23	Buy	49.81	8,500	423,385	35,500	Nov 21 07:01 PM
Powell Ann	EVP, Chief Human Resources	Aug 24 '23	Sale	61.25	17,986	1,101,642	27,868	Aug 28 05:28 PM
Plenge Robert M	EVP, Chief Research Officer	Aug 03 '23	Sale	61.14	732	44,754	6,584	Aug 07 05:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMY

Bristol-Myers Squibb Co.

Upgrade your FINVIZ experience